Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Basch, E
Right arrow Articles by Ulbricht, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Basch, E
Right arrow Articles by Ulbricht, C
American Journal of Health-System Pharmacy, Vol 60, Issue 4, 356-359
Copyright © 2003 by American Society of Health-System Pharmacists


Articles

Bitter melon (Momordica charantia): a review of efficacy and safety

E Basch, S Gabardi, and C Ulbricht


The pharmacology, clinical efficacy, adverse effects, drug interactions, and place in therapy of bitter melon are described. Bitter melon (Momordica charantia) is an alternative therapy that has primarily been used for lowering blood glucose levels in patients with diabetes mellitus. Components of bitter melon extract appear to have structural similarities to animal insulin. Antiviral and antineoplastic activities have also been reported in vitro. Four clinical trials found bitter melon juice, fruit, and dried powder to have a moderate hypoglycemic effect. These studies were small and were not randomized or double-blind, however. Reported adverse effects of bitter melon include hypoglycemic coma and convulsions in children, reduced fertility in mice, a favism-like syndrome, increases in gamma-glutamyltransferase and alkaline phosphatase levels in animals, and headaches. Bitter melon may have additive effects when taken with other glucose-lowering agents. Adequately powered, randomized, placebo-controlled trials are needed to properly assess safety and efficacy before bitter melon can be routinely recommended. Bitter melon may have hypoglycemic effects, but data are not sufficient to recommend its use in the absence of careful supervision and monitoring.
 



This article has been cited by other articles:


Home page
Diabetes Spectr.Home page
L. Shane-McWhorter
Dietary Supplements for Diabetes: An Evaluation of Commonly Used Products
Diabetes Spectr, October 1, 2009; 22(4): 206 - 213.
[Abstract] [Full Text] [PDF]


Home page
cfpHome page
R. Nahas and M. Moher
Complementary and alternative medicine for the treatment of type 2 diabetes
Can Fam Physician, June 1, 2009; 55(6): 591 - 596.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
P. V. Nerurkar, L. Pearson, J. T. Efird, K. Adeli, A. G. Theriault, and V. R. Nerurkar
Microsomal Triglyceride Transfer Protein Gene Expression and ApoB Secretion Are Inhibited by Bitter Melon in HepG2 Cells
J. Nutr., April 1, 2005; 135(4): 702 - 706.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society of Health-System Pharmacists.
Advertisement